| HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the fourth quarter ended December 31, 2024. |
| Key fourth quarter metrics (all percentage changes compare 4Q 2024 to 4Q 2023 unless otherwise noted): |
- Revenues totaled $18.285 billion
|
- Net income attributable to HCA Healthcare, Inc. totalled $1.438 billion, or $5.63 per diluted share (which includes an estimated $0.60 per diluted share unfavourable impact from Hurricanes Helene and Milton)
|
- Adjusted EBITDA totalled $3.712 billion
|
- Cash flows from operating activities totalled $2.559 billion
|
- Same-facility admissions increased by 3.0 per cent and same-facility equivalent admissions increased by 3.1 per cent
|
| "We finished 2024 with strong business fundamentals that were consistent with previous quarters," said Sam Hazen, Chief Executive Officer of HCA Healthcare. "The first half of the current decade, which ended in 2024, proved to be another period of long-term growth for the company and resulted in operational improvements across key performance indicators and greater value for our patients, employees and shareholders. These accomplishments are a testament to the incredible work of our teams, and position us well for the future." |
| Revenues in the fourth quarter of 2024 totalled $18.285 billion, compared to $17.303 billion in the fourth quarter of 2023. Net income attributable to HCA Healthcare, Inc. totalled $1.438 billion, or $5.63 per diluted share, compared to $1.607 billion, or $5.93 per diluted share, in the fourth quarter of 2023. Results for the fourth quarter of 2024 include losses on sales of facilities of $195 million, or $0.59 per diluted share, primarily related to the pending sale of a hospital facility in California. Results for the fourth quarter of 2023 include gains on sales of facilities of $7 million, or $0.03 per diluted share. |
| For the fourth quarter of 2024, Adjusted EBITDAtotalledd $3.712 billion, compared to $3.618 billion in the fourth quarter of 2023. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release. |
| Same-facility admissions increased by 3.0 per cent and same-facility equivalent admissions increased by 3.1 per cent in the fourth quarter of 2024, compared to the prior year period. Same facility emergency room visits increased by 2.4 per cent in the fourth quarter of 2024, compared to the prior year period. Same-facility inpatient surgeries increased by 2.8 cent, and same-facility outpatient surgeries declined by 1.3 per cent in the fourth quarter of 2024, compared to the same period in 2023. Same facility revenue per equivalent admission increased 2.9 percent in the fourth quarter of 2024, compared to the fourth quarter of 2023. |
| Year Ended December 31, 2024 |
| Revenues for the year ended December 31, 2024, totalled $70.603 billion, compared to $64.968 billion for the year ended December 31, 2023. Net income attributable to HCA Healthcare, Inc. was $5.760 billion, or $22.00 per diluted share, compared to $5.242 billion, or $18.97 per diluted share, for the year ended December 31, 2023. Results for the year ended December 31, 202,4 include gains on sales of facilities of $14 million, or $0.04 per diluted share. Results for the year ended December 31, 20,23 included losses on sales of facilities of $5 million, or $0.04 per diluted share. |
| For 2024, Adjusted EBITtotalledled $13.882 billion, compared to $12.726 billion in 2023. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release. |
| Balance Sheet and Cash Flows from Operations |
| As of December 31, 2024, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $1.933 billion, total debt of $43.031 billion, and total assets of $59.513 billion. During the fourth quarter of 2024, capital expenditures totalled $1.285 billion, excluding acquisitions. Cash flows provided by operating activities in the fourth quarter of 2024 totalled $2.559 billion, compared to $2.674 billion in the fourth quarter of 2023. |
| During the fourth quarter of 2024, the Company repurchased 4.739 million shares of its common stock for $1.700 billion. The Company had $764 million remaining under its repurchase authorization as of December 31, 2024. As of December 31, 2024, the Company had $7.986 billion of availability under its credit facilities. |
| Share Repurchase Program |
| The HCA Healthcare, Inc. Board of Directors has authorized an additional share repurchase program for up to $10 billion of the Company’s outstanding common stock. Repurchases will be made by applicable securities laws and may be made at management’s discretion from time to time in the open market, through privately negotiated transactions, or otherwise. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. |
| Dividend |
| HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.72 per share on the Company’s common stock. The dividend will be paid on March 31, 2025, to stockholders of record at the close of business on March 17, 2025. |
| The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition, results of operations, and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations. |
| For the full document click the link below: |
| HCA Healthcare, Inc. |
| Stay ahead of the curve! Subscribe to InsidEntity for daily updates on all your favourite companies. |
